Healthcare News 11

• "I am Not a Doctor but I Play One on TV...."
• "Minute Clinics" are here to stay
• "RECORD" would bring record number of approved targted agents for renal cancer
• "Targeted" approach in both Ovarian and endometrial tumors? Very interesting and potentially effective!
• 1000 genomes - personalized medicine on sight
• A big positive for kids, and a plus for Amegn and Wyeth
• A brief commentary on neuropathic pain market:Pipeline insight?
• A caveat pertaining to studies of Postmenopausal Vaginal Syndrome
• A good deal
• A good tool for children
• A MATCH MADE IN HEAVEN.
• A merger that makes sense.
• A new move to gene therapy - World renowed molecular researchers collaboration
• A new NNRTI strong,safe and respectful of other similar drugs next use
• A Possible Botox "Black Box" Warning Will Serve No Purpose
• A rose by any other name-
• a safer steriod
• A Study With The Wrong Endpoints
• A third world country balking at the cost of high priced cancer drugs their citizens can't afford? Go figure....
• A treatment alternative for mania with minimal weight gain
• about time
• ABT-874 for Moderate to Severe Chronic Plaque Psoriasis
• Acambis’ Herpes Vaccine, dl5-29 HSV-2 Vaccine, Shows Promise for Genital Herpes
• Accelerated approval for Avastin: Just the beginning
• Acne Care Remains True to Form
• Acne Treatment for Adolescents
• ADVANCED EOA is not so advanced...Revisiting a common old condition with new answers.
• Again, too simplistic an approach
• Alvesco... Finally, a Safe inhaled steroid
• Alvimopan outlook
• AMAG Pharmaceuticals Ferumoxytol Not likely to Capture Market share
• American Cancer Society is promoting money in CaCa analysis?
• Amgen : Future is NOT that Bright!!!
• Amgen and J & J: FDA adding insult to injury #5
• Amgen versus Merck
• Amgen, ESA Safety in Oncology, and FDA's ODAC Panel
• Amgen: Rose Colored Glasses??
• Amgen's prospects?? +/-?
• Amgen's questionable future
• An issue of prescription coverage
• An Unhappy Trend
• An Uphill Battle Ahead – Luvox CR Approved for OCD and Social Anxiety
• Anesthesia in Colonoscopies: I have an idea for a clinical trial!
• Anesthesiologists' Reimbursement is of Concern to Payors
• Another blow to combined estrogen-progesterone therapy
• Another drug for fibromyalgia
• Another dumb governmental idea
• Antidepressants are (not) useless
• Antihistamie for sleep?
• Antisense Technology and Medical Breakthroughs - Alnylam (ALNY) and ISIS (ISIS) Lead the Way
• Apple (Aapl) IPhone: Move Over Blackberry (RIMM) , "Apple Means Business"
• Are Avastin and Herceptin complementary treatment choices?
• Are second (tandem) transplants dead in MM and what does it mean to PHARMA
• Are vaccines an effective prevention tool?
• ARIAD Pharmaceutical's Deforolimus: mTOR inhibition revisited
• Artificial Cervical Disc Looks Promising
• AS1409 : Not so novel drug in an already crowded market
• At What Age Should Contact Lenses Be Considered for Children?
• Attempting to address a major drawback of current treatments
• Avastin (Genentech): Approval in breast cancer? It would be the correct thing to do!
• Avastin (Genentech, Roche) in Breast Cancer: The Second Time is a Charm with the FDA???
• Avastin Approved in Breast Cancer: the correct thing was done
• Avastin for Breast Cancer: Here Today Gone Tomorrow? No
• Avastin for recurrent breast cncer: improvement in time to progression may be enough for FDA approval!!!
• Avastin In Breast cancer
• Avastin: Not for every one with breast cancer, but benefit is real for selected patients.
• Bad for all
• Bad move
• Bausch makes foray into presbyopic arena
• Bausch moving forward after takeover by Warburg Pincus
• BCP have known side effects
• Benefits of TELESCOPIC lens implants important for those already effected by macular degeneration
• Better PR needed
• Better product
• Big Benefit for Adult Population
• Biosimilar versus Generic Drugs
• Biovitrum's BVT.28949 Glaucoma Medication Results are Disappointing
• Blue Cross Mass. New Payment Plan - A rose by any other name would smell as ?sweet
• Blue Cross Plan is capitation in a worse plan
• Body composition changes after bariatric surgery
• Boehringer Ingelheim today announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency has issued a positive opinion to recommend marketing authorisation of their novel, oral direct thrombin inhibitor, dabigatran etexilate. May well replace current agents!
• Botox competitors can't come soon enough
• Botox competitors to make market interesting
• Botulinum Toxin Type A has long-term efficacy and safety for glabellar skin lines
• Breast Cancer
• Breast Cancer Test Valuable Tool for in Assessment of Tumor Recurrence in Postmenopausal Women
• British Study Is Another Knock - But Not A Knock-Out for Very Effective Medications
• BVT28949. A Possible Adjunct To Prostaglandin Analogs.
• CA e-pedigree: Delay to 2011 Now Likely
• Can Google set the standard for EMRs?
• Can Hematiide Replace Aranesp/Procrit for Chemotherapy Induced Anemia?
• Can Technology Slow the Growth in Health Care Costs
• Cancer Risk with Drug Treatment in Autoimmune Diseases a Complex Picture
• Capitation by any other name is still capitation
• Cardinal Health has renewed focus and new leadership
• Cardinal Health: Fourth Facility Now At Risk
• Cardinal Health's Customer Problems Deepen
• Cardiotoxicity associated with tyrosine kinase inhibitors
• Care in its use
• CATT Trial will Likely sink Genetech's (DNA) Lucentis for AMD Treatment.
• CeNeRx's Tyrima for depression - substantial potential from a proven approach.
• CEP-18770 (Cephalon & Cell Therapeutics Europe) an oral proteosome inhibitor: Millenium beware
• Certainly should help sales volume!
• Changing the Society is the Way of the Future to Bend the Medical Trend
• Chantix may worsen preexisting Mania and Schizophrenia in some patients who use it for smoking cessation.
• Chantix--too good to be true
• China is the largest exporter of drugs or drug's ingredients and FDA does not have resources to check the quality of the majority of the imported as well as the USA produced generic drugs.
• China's Regulatory Shortfalls cuts into US Big Pharma Profits
• Chinese Heparin Debacle May Cause World Wide Shortage for Dialysis Providers
• Cholesterol lowering: to advertise or not???
• Choosing the best treatment for wet AMD.
• Cialis for Boy Scouts
• Cimzia(R) (certolizumab pegol) will be reviewed by the FDA for biologics licence application
• Circassia's anti-allergy drug
• cllaboration between academia and industry
• Collagenex Rx for psoriasis
• Colorectal Cancer
• Comment on New drug for HRPC(Hormone Refractory Prostate Cancer)
• Compliance Leads the Way for Quality Care
• Congress Debating Mental Health Parity Bills: Must Not Rely on Diagnosis Alone
• Crestor Trial Timing is Interesting
• CVS and other related clinics may have the right approach!.
• CVS clinics as seen by a pediatrician
• daily use Cialis---a good idea!
• Decreasing the risk of complications in the treatment of wet AMD.
• Deep Brain Stimulation for Treatment Resistant Depression – The Race is On
• Dementia: the same treatment regardless of the age of onset?
• Denosumab: Unlikely to be the " White Knigt" for Amgen
• Despite Opening 16,000 New Accounts, E-Trade Reports Losses In Total Assets Managed
• Details on AstraZeneca's Direct-to-Pharmacy Model
• Diabetes is a cardiac risk equivalent
• Diabetes Mellitus Trial: Disclaimer: I am not a diabetes expert but I have been a physician x 39 years....
• Diabetics Receiving Cholesterol-Lowering Drugs
• Did Amgen use improper tactics to raise sales of Enbrel?
• Distributors Face Rising Compliance Costs
• Diversion Risk for AmerisourceBergen?
• Do not count your chickens before they hatch
• Does DM in its Current Form Work?
• Dont be surprised that ENHANCE STUDY did nothing of the sort!
• Dov’s Triple Reuptake Inhibitor Enters Phase II Major Depression Trial
• Doxepin is new again
• DPI for 4+ year olds - love it!
• Dr. Folkman : apioneer in the fiels of anti-angiogenesis, but the anti-cancer battle still NOT won
• Drivers and Passengers: The complexity and heterogeneity of mutational signatures in cancer means that sequencing becomes the easy part.
• Drop outs: a new key to unlocking cell survival and proliferation pathways in cancer
• Drug Rep Licenses in D.C. Will Have no National Effect on Sales
• Drug reps: a double edged sword?
• Dumb and dumber
• Dying patient denied access to experimental drugs is contrary to common sense and discovery of new treatments.
• Effect of Punctal Plugs in Patients with Low Refractive Errors Considering Refractive Surgery
• Effective treatment of MS
• Eli Lilly & Company Develops Novel Antipsychotic for Treating Schizophrenia
• Enbrel effective in pediatric psoriasis
• Enbrel in pediatric psoriasis
• Enbrel Significantly Improved Psoriasis in Children and Adolescents
• ENHANCE trial results will dramatically decrease Vytorin and Zetia sales.
• Erythropoiesis Stimulating Agents could be further restricted by Payers (Medicare, PBMs, and Healthplans)
• Ethics and time
• Excellent posible new addition to Antidepresant trreatment
• Exciting new treatment for OCD and Social Anxiety Disorder
• Expect very dramtic and continued decreases in scripts for vytorin and zetia
• Expensive to see representatives in the office
• Extending The Life of a Branded Drug
• Factors to Consider in Implementing Pay for Performance Programs.
• Failure to reach efficacy endpoint - implications of Everest trials for stroke recovery
• FDA & Epo: Not as bad as expected!
• FDA allowing info on non FDA approved uses? A bonus for Pharma but a nightmare for insurers.
• FDA Approval of Abilify for Pediatric Bipolar disorder is a Major Advance
• FDA approval of Luvox CR is good news for psychiatrists!
• FDA Botox warning unlikely to limit cosmetic use
• FDA Correctly Approves Avastin for Breast Cancer Based on PFS Advantage
• FDA faults drug plants; AP faults the FDA; Identify the Root Cause(s) and Industry heal thyself.
• FDA Panel of Injectafer Safety, Impact for Galenica and AMAG
• FDA panel recommendations means less sales of ESA'a and negative implications for Amgen
• FDA Will Have to Change
• Fears of safety and fears of a black box warning.
• First announcement of data (very limited) from InterMune's HCV protease inhibitor ITMN-191
• First Impressions Carry the Day and the Year -Vytorin Loses in ENHANCE
• Focusing on the delivery system, not the drug
• For Docs to Make an Extra $100K per Year..."There's No Place Like Home"
• Fosamax generic...
• Fraud: Inevitable no matter who is in charge
• Galderma has Strengthened its Position as a Leader in Dermatology
• Galvus Receives Approval, But A Larger Battle Remains
• Galvus spells hassle
• Gamunex in CIDP
• Gardasil for boys: Not so tough sell!!!
• Gardasil for males--helping to fill in the gaps
• Gardasil: Cervical Cancer Vaccine for Boys?? Can you say disingenuous?
• Gene Directed Therapy: I told you so!! Roche Holding on the right track!
• Genentech Cabilly Patent Rejection Affects Revenues Not Genentech's Methods of Production
• Genentech's future for Avastin depends on FDA
• Genetic risk stratification in intermediate risk AML
• Genetic Testing
• Genzyme's Cerezyme: When is enough enough
• Geographic Location Key In Walk-In Clinic Locations
• GlaxoSmithKline (GSK) oral Topotecan: Impact? Use?
• Glutamate - a New Paradigm in Approaches to Mental Illness - or An Expensive Detour (?)
• Glutamate drugs for schizophrenia--too soon to tell
• Good attempt at risk stragedy but will not be accepted by doctors
• Good but not that much better
• Good news for patients with AD or MCI
• Good timing for Abbott
• Google is moving forward to store patient's health records - Is this a safe approach from Google?
• Great concept
• Great if it works
• GSK's Rx for RLS
• GVAX (Cell Genesys) In Metastatic Prostate Carcinoma (MPCA). I'm Impressed So Far!
• Hair follicle analysis directing cancer care- What if the chemo or mother nature leaves you bald???
• Hair follicle gene expression profiling as a means of assessing new cancer treatments
• Health Care Information Technology Funds Reserved
• Health Care IT 2008 outlook
• Healthcare and Molecular Diagnostics
• Healthways Fires Back Over CMS Release of Phase I Results
• Heed what people say
• Hematide ; Just another ESA?
• Hematide: A safer ESA??
• Heparin Also Used in Pets
• Heparin: Unfractionated Heparin, more expensive, less effective and dangerous compared to low molecular weight varieties
• Hepatitis C: little-recognized nitazoxanide (Alinia, Romark) shows remarkable activity in combination therapy for HCV genotype 4
• How do we like our drug reps? Nothing new here but the reps' problems are increasing.
• How much of a "good" thing does one need?
• How to Drive up Hospital Costs and Decrease Revenue
• How to market new drugs to doctors
• How well does Enbrel work for pediatric psoriasis?
• How will Apremilast (CC-10004) Affect the Treatment of Psoriasis?
• How will this discovery affect future psoriasis therapies?
• HUMIRA versus Enbrel
• Humira will overtake Enbrel in the TNF alpha market
• I couldn't agree more
• Ideal study is less than "ideal"
• IDEAL study shows equivalent efficacy of Ribavirin + PEG-Intron 1.5 vs. 1.0 mcg/kg vs. Pegasys for HCV genotype 1
• Implications for acceptance by FDA of Treanda for NHL
• improve Overall survival in prostate cancer
• In phase 3 ACHIEVE study, Albuferon at 1200 mcg/2 weeks is switched to 900 mcg
• Increased regulation will be the norm
• Infliximab Works Well for Scalp, Trunk, and Extremities Affected by Psoriasis
• Influenza Vaccine May Get Much Needed Boost
• insurance companies can help
• Interesting but not my real world!
• Intriguing, but much more info needed
• Inverness to Acquire Matria Healthcare for $900MM
• Is it a truely new kid on block or and old with new attachments
• Is This a Meaningful Change?
• Is this Going to be the One Stop Shop for Health Information?
• Is time to progression equivalent to overall survival endpoint in metastatic breast cancer patients?
• It is dangerous move
• It is morally reprehensible that the NEI was forced to act and create the CATT trial
• It is time to cover ALL Americans, equally
• it is time to fight against big pharm
• It is Tough to Practice Good Medicine and Make a Profit
• It's About Being a Healthcare Company Rather than a Pharmaceutical Company
• Its all in the mind
• Joint collaboration between NRDL and Eli Lilly and Company - Is this going to work ?
• Judah Folkman was an amazing and inspirational medical pioneer
• Just a transition stage
• Justified concerns for growing genetic tests without FDA approval
• Juvista Improves the Appearance of Scars
• Keeping the privacy of health data.
• Large Employers Are Deciding to Take Measures to Drive Health System Reform
• Legal Victory by Pharmacy Saves AWP (for now)
• Let the People Decide
• Lilly's (LLY) Long-Acting Zyprexa May Have a Role in Non-Compliant Patients
• Lilly's (NYSE: LLY) Zyprexa's Long-Acting Injection Stumbles - for Now (?)
• Lilly's long-acting injectable olanzapine (Zyprexa): added value, but metabolic limitations remain
• Low Molecular Weight Heparins (LMWH): a windfall!!
• Lundbeck’s Pipeline Advances with Lu AA34893 for Bipolar Depression
• Lung Cancer
• Lung Cancer: Make way for Sutent (Pfizer)
• Luvox CR (Jazz Pharm. - Nasdaq: JAZZ) Will Drive OCD/SAD Sufferers to Treatment
• Luvox CR Approved for OCD and Social Anxiety--Where's the Beef?
• Major Boon for Diabetes Companies, if only...
• Major Win For Glaxo with Xenoport for Restless Legs syndrome -- Next Blockbuster?
• Malignancies from RA drugs
• Managed-care P-4-P benefits
• Many contenders for one big prize
• MAO-B Inhibitor for Smoking Cessation (EVT 302)
• Medical errors and patient safety
• medicare should pay for well exams
• MEM 3454, A Hopeful New Drug Treatment for Cognitive Impairment in Schizophrenia?
• Merck Developement of Anacetrapib not as Risky as it may appear!
• Merck Developement of Taranabant not as Risky as it may appear!
• MHS key industry event
• Molecular Diagnostics
• More Data on Avastin Benefit in Breast Cancer But Still PFS and not OS Improvement
• More fuel for the fire
• More misleading Provenge data from Dendreon
• More non-specific treatment for smoking
• More questions raised than answers
• More Support for Rituxan in CLL
• More than 1 mechanism and preclinical activity in hormone sensitive and resistant cancer
• More than just AVASTIN
• MRSA
• MRSA Test Launched in the US
• Need for cardiac evaluation in patients receiving novel cancer treatments
• Needs to come off the market
• Neuropathic Pain: Large Market- Few Good Options
• Neuropilin-2 : An interesting class of agents
• New Approach for an Influenza Vaccine
• New Cancer Drugs: Distinguishing between genes 'sinning' and those 'sinned against'.
• New DDP-4 Inhibitor
• New Drug for BPH to enter a crowded market
• New molecule for the treatment of rheumatoid arthritis with minor toxicity.
• New Pharmasset/Roche HCV polymerase inhibitor R7128 is promising in combination therapy
• New promising agent for glaucoma treatment
• New promising glaucoma agent for glaucoma treatment
• Newer and More Effective Adjuvants are a Start
• Nexavar (Onyx & Bayer): down & out???
• Nice,if you can get it.
• Nitromed gone and soon forgotten
• NNRTIs are not obsolete
• No effect.
• No increased risk of haematopoietic malignancies and solid cancers after treatment with TNF antagonists
• No need for bovine bone
• NO SURPRISE.
• Not a quick fix
• Not Close to In Vivo Use yet
• Not new news
• Novartis's Everolimus: On it's way to being a competitor for Wyeth's Torisel.
• Novel Antidepressant Agent Tyrima(TM) has Real Potential But Efficacy Not Fully Evaluated
• Novel molecules and diagnostic tests
• Nplate: An effective parenteral therapy for refractory chronic ITP
• Obsession with glucose in type 2 diabetes overlooks importance of real CVD risk factors
• Offshoring clinical trials
• Once Daily Cialis Will Be a Niche Application
• One treatment more in the antipsoriatic topicals armamentarium
• Only very long-term studies will tell
• Ophena is a Me-Too Drug with an Impractical Mode of Administration
• Oral Toptecan: Efficay with narrow market and limited use
• Outsourcing clinical trials is outsourcing ethical standards as the price for global profits
• Outsourcing of compassionate use of drugs?
• Ovarian Cancer Test
• Padova Italy - 10 years on : Patient Safety: Things are getting better!
• Panzem and Avastin Active in Carcinoid Tumors? I'm not so sure....
• Patient to Patient doctor office ratings
• Patients out of the ER into the clinic
• Pay for Performance Can Drive Physician Behavior, but don't Forget the Patient
• Pay for Performance Continues to Pay Off
• Payon is a firm developping antithrombotic drugs such as desmoteplase ; we used this drug in our department two clinical trials DIAS and DIAS II for treatment of acute ischemic stroke , we are aware about side effect and we are interested in new developpment in the field of antithrombotic therapy by PAYON.
• PBMs and managed care will be happy-patients too
• PDE4 and RA
• Pediatric Contact Lens Patients
• PEG Intron goes before ODAC in March 2008
• Penwest Favicon has promise in the long term
• performance or cost
• Periodic Inspections by WHO/FAO Codex Alimentarius Teams
• Pharmacy Profits & Part D
• Phase 2 trials show significantly improved scars
• Phosphagenics Topical Retinoic Acid Clinical Trial Initiated
• Phosphagenics’s Retinoic Acid will Enter a Crowded Field if Approved
• Picoplatin (Poniard) in Metastatic Prostate Cancer: Why not?
• Plausible new mechanism, but infection risk may be no better than TNF approach
• Possible advantage of Denosumab over fosamax
• Possibly more ways of fighting against glucocorticoid related osteoporesis
• Potency not the critical parameter
• POTENTIAL PARADYM SHIFT IN MANAGEMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
• Potentially dangerous drug-use with caution
• Prasugrel-The next Plavix ? ?
• Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia
• Premature declararation without in depth analysis.
• Preventing Bariatric Surgery Deaths
• Preventive care again...just not a popular item in US Healthcare policy
• Previous FDA track records are against Genentech but don't disregard political activism!!!
• Procrit, Aranesp, Epogen: OMG (O my God) now JAMA piles on.
• Promising data, exciting target, still some uncertainty on safety
• Promising developmental programme by Memory Pharmaceuticals & Roche for MEM 3454 in Schizophrenia
• Promising News for AMD
• Prostate cancer: Will it be used? Yes!! Will the insurers pay for early detection??
• Public Health Agency of France Gets it Right on HPV Vaccine
• Quality Needs to be a Cultural Norm
• Quality of physician-owned hospitals is better than general hospitals
• Quality or Profit ?
• Questions about bleeding, proper dose and appropriate patient subsets will limit use
• Quicker diagnosis will shorten hospital stays and reduce costs--but prevention is key
• Radical health changes to wait until the election: Is this practical?
• Rating Doctors the Travelocity Way
• Renovo's Juvista product holds promose
• Right data, wrong interpretation?
• Rising prospect for Genentech - a financial review
• risk shifting
• Rituxan: A slightly new twist. Beneficial to who??
• Rituxan: Another use for Vitamin R???
• Roche Herceptin targeted cancer drugs
• Roche Holding AG : Avastin in the EU receives approval for wider applicability
• Roche to Acquire Ventana for $89.50 and Expands its Leadership Position in Clinical Diagnostics
• Sales Reps lose out in bid for Physicians' attention.
• Same old same old....
• Sanofi's Gardasil Should Be As Widely Accepted in Europe as in US
• Science ahead of its time
• Scratch the Ortho Evra Patch for Birth Control
• Sepsis
• Shake Out Normal in Pursuing the "Next Great Idea"
• Show me a hacker proof system first
• side effect and cost issues
• SILENOR -- A Sleeper among Hypnotics
• Simcor will likely not have much market share
• Sirilmous: efficacy even in Non-maliganant tumors
• Sirolimus (Macusight) is Latest Player to Enter the AMD Market
• Sirolimus and mTOR inhibition
• Slanted Reporting on Anti-depressants
• SNPing to identify the genetic basis of prostate cancer
• Somaxon and Silenor, A Win-Lose Situation?
• Somaxon Pharmaceuticals, Inc. will not produce a shining star when it launches SILENOR™
• Somaxon's (SOMX) Silenor: Recycling Old Drugs
• Some Physician-owned Hospitals Are Unsafe
• Specific Considerations When Merging Two Corporate Cultures
• Statins: I Knew It, I Knew It, I Knew It......
• Stay Alert for Registration Trial Results
• Sterile Injectables Contract Manufacturing Market Outlook
• Strike One for Sutent
• Subcutaneous drug will have a role in palliative care setting
• Successful management strategies for Parkinson's disease - how long will this last?
• Such partnerships may become the norm following the '1000 Genomes Project' :
• Supreme Court makes correct decision on experimental drugs
• Sustainable Cost Cutting Efforts Through Strategic Partnerships
• Sutent (Pfizer) causes heart failure?? Advantage Nexavar (Bayer/Onyx) and Torisel (Wyeth)
• Sutent and NSCLca
• Sutent for NSCLC: Role for combination therapy
• Sutent's " Cardiac Worries" grow: Nexavar and Torisel to benefit
• Targeting the Uninsured is an Excellent Idea
• Technology is all too often the CAUSE of increased health care spending
• Terminally ill patients cannot access drugs not approved by the FDA: ethical and legal issues are established
• Tests that do not lead to proven therpies are worthless and may cause more harm than good
• Teva Camptosar: significance?
• TEVA may compete with Pfizer for market share of Camptosar
• TEVA will rise above
• TEVA wins first generic approval of Foxamax®, expect TEVA to hold market share
• Teva's generic Irinotecan will gradually cut into the brand name use
• The "cure" for Macular Degeneration? Maybe!
• The "uninsured" : a lucrative market , but proper and simple targeting is required!!!
• The Darkside of Hospital Pharmacy Outsourcing?
• The DEA's Anti-Diversion Strategy
• The FDA givith (Amgen's Nplate) and takith away (Amgen's Aranesp)
• The Future of Stereotaxis
• The Genie is Out of the Bottle
• THe hoopla is premature
• The impact on Vytorin and zetia sales will be modest reduction after the release of ENHANCE data
• The Joint Commission's Push for a National Healthcare Data System
• The Myth of Drug Price Transparency
• The news of botox deaths will not effect continued use of the drug
• The Outlook of AS1409 for Melanoma
• The rational use EPOs is of paramount importance in cancer patients
• The rational use of a useful class of agents
• The Supreme Court got it right
• The US not quite ready to throw in the iv pole
• The way to go!
• There are opportunities to keep market share, and one set of words describes it "Life Cycle Management"
• There May Soon be "Goo Goo Googley Eyes" on Your Personal Health Records
• They would!
• This acqusition, and others, represent a significant upgrade of Alphatec's portfolio
• Time is of the essence
• To consider the possible role of the new NNRTI etravirine in the treatment of HIV infection
• Treanda Likely Big Winner in Indolent NHL
• Treanda will expand Cephalon's Oncology presence with other drugs on the horizon
• Treanda: A winner for Cephalon in Low grade non-Hodgkin's lymphoma (NHL) AND chronic lymphatic leukemia (CLL).
• Treatment of pediatric reflux laryngopharyngitis and exacerbation of laryngomalacia.
• Trying to make more profits off the uninsured! Just adding to the problem!
• Tysabri in Crohn's Disease
• Understanding the effects of statins in low risk patients.
• Use of Imported Intermediates or Final Materials for US Drugs Certain to Continue
• Use of incentives in wellness programs: CAUTION
• Ustekinumab for moderate to severe chronic plaque psoriasis
• Ustekinumab Shows Great Promise for the Treatment of Psoriasis
• Velcade: 1st line indication probable, but is it really better and easier??
• Vidaza use in the EU. I'm surprised it wasn't already in use.
• Wal-Mart's PBM Game Plan
• Warning from FDA about contaminated syringes
• Warning on A1C Targets and Diabetes Death in ACCORD Trial
• Was inevitable
• Wellcare Still has Some Troubles
• Wellness Programs
• WellPoint Disappoints, Cites Increased Medical Costs as One Reason
• Wellpoint has seen the Doctor and the Prescription is set to work
• What about continuity of care?
• what about prevention?
• What side of the fence are you on?
• What will you do if and when your hospital closes?
• Where is the profit in medical record storage?
• While Baxter and APP "fiddle" GSK's Lovenox should jump into the void
• Whoever wins the oral anticoagulant race gets the gold
• Why not end capitation and switch to retainer fees?
• Widening participation in vaccine development for developing countries - a good step from Novartis
• Will Crohn's management follow RA?
• Will not change much
• Will only have meaning if correct strains are in the vaccine
• Will this Hospital's Quest to Eliminate Medical Mistakes Spark a National Movement?
• Will TRICARE Boost WAC for PBM Pricing?
• Win for Talecris' Gamunex IVIG in Inflammatory Polyneuropathy
• Wouldn't you want 5 1/2 more months if you had metastatic breast cancer?
• Wyeth's Sirolimus: the tip of an iceberg.
• XL139: BMS gamble??
• XL-139: profitable deal for Exilexis but very risky for BMS
• XL-184: an RTK inhibitor with no apparent incraesed cardiac toxicity
• Xyzal--Just overpriced Zyrtec
• Zagat Guide for Doctor's Offices
• Zylet (Bausch & Lomb) as as good and safer than Tobradex (ACL) for Blepharitis.
• ZymoGenetics' rDNA Thrombin Gets FDA Nod; The Battle vs King, J & J, Baxter Begins!
• Zyprexa safety
• Zyprexa: is it OK to RX ?
• Zyprexa® Long-Acting Injection (LAI): Far from a Slam-Dunk